Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.84 (2.05%)
Data as of 07/13/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
06/27/18The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data
–More than 1,550 patient-years of safety data accumulated to date – a three-fold increase over total patient exposure through Phase II trials– –At the time of IDMC review, [substantially] all patients in Phase III trials had received two doses of inclisiran or placebo– –Phase III trials of inclisiran progressing as planned with no material safety observations to date– PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 27, 2018-- The Medic... 
Printer Friendly Version
06/26/18New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 26, 2018-- The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando (ADA 2018). Professor Lawrence Leiter, Director of the Lipid Clinic, Associate Directo... 
Printer Friendly Version
05/07/18The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
Inclisiran reduced key atherogenic lipoproteins – found in the blood of individuals at high risk of heart attacks – back to normal in 68% to 90% of patient studied Inclisiran drove sustained lowering of key atherogenic lipoproteins – non-HDL-C, ApoB, VLDL-C and Lp(a) Pre-specified analysis of ORION-1 Phase II study featured in late-breaking session at 86th Annual European Atherosclerosis Society Congress Analysis acc... 
Printer Friendly Version
04/30/18The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
–Data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on Day-1, Day-90 and every six months thereafter across a wide range of dyslipidemia patient populations and sub-groups– PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2018-- The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.